butyl-methallyl-amine | 6045-11-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: butyl-methallyl-amine
• 英文别名: 3-Butylamino-2-methyl-propen-(1)；N-(2-Methyl-2-propen-1-yl)-1-butanamine；N-(2-methylprop-2-enyl)butan-1-amine
• CAS: 6045-11-0
• 化学式: C₈H₁₇N
• mdl: MFCD16471846
• 分子量: 127.23
• InChiKey: JHYHIRODANDVJH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  9
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  butyl-methallyl-amine 、 丙烯酸乙酯 在 dichloro(pentamethylcyclopentadienyl)rhodium (III) dimer 、 silver(I) acetate 作用下， 以 乙腈 为溶剂， 反应 6.0h， 以54%的产率得到ethyl 2-(1-butyl-4-methyl-1H-pyrrol-2-yl)acetate
  参考文献：
  名称：

  Synthesis of Pyrroles through Rhodium(III)-Catalyzed Reactions of Allylamines and Alkenes

  摘要：

  Pyrrole derivatives are generated in reactions of allylamines with alkenes that are promoted by a Rh(III) catalyst in the presence of AgOAc. This process, which involves chelation assisted C-H bond activation and N-annulation, is applied to a three step synthesis of Zomepirac.

  DOI：

  10.1021/acs.orglett.5b01811

文献信息

• FUSED PYRIDAZINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT
  申请人：Seko Takuya

  公开号：US20080261947A1

  公开（公告）日：2008-10-23

  Fused pyridazine derivatives represented by formula (I) or pharmaceutically acceptable salts thereof (wherein each symbol has the meaning as defined in the specification.). Because of inhibiting poly(ADP-ribose)polymerase, the compounds represented by formula (I) are useful as preventives and/or remedies for various ischemic diseases (in brain, cord, heart, digestive tract, skeletal muscle, retina, etc.), inflammatory diseases (inflammatory bowel disease, multiple cerebrosclerosis, arthritis, etc.), neurodegenerative diseases (extrapyramidal disorder, Alzheimer's disease, muscular dystrophy, lumbar spinal canal stenosis, etc.), diabetes, shock, head trauma, renal failure, hyperalgesia, etc. Moreover, these compounds are useful as agents against retroviruses (HIV etc.), sensitizers in treating cancer and immunosuppressants.

  式（I）所表示的融合吡嗪衍生物或其药学上可接受的盐（其中每个符号的含义如规范中所定义）。由于抑制了聚(ADP-核糖)聚合酶，式（I）所表示的化合物可用作预防和/或治疗各种缺血性疾病（在大脑、脊髓、心脏、消化道、骨骼肌、视网膜等部位），炎症性疾病（炎症性肠病、多发性硬化症、关节炎等），神经退行性疾病（锥体外系障碍、阿尔茨海默病、肌萎缩症、腰椎管狭窄等），糖尿病、休克、头部创伤、肾功能衰竭、高痛感等。此外，这些化合物还可用作抗逆转录病毒剂（HIV等）、治疗癌症的增敏剂和免疫抑制剂。
• Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP2281818A1

  公开（公告）日：2011-02-09

  Fused pyridazine derivatives represented by formula (I) or pharmaceutically acceptable salts thereof (wherein each symbol has the meaning as defined in the specification.). Because of inhibiting poly(ADP-ribose)polymerase, the compounds represented by formula (I) are useful as preventives and/or remedies for various ischemic diseases (in brain, cord, heart, digestive tract, skeletal muscle, retina, etc.), inflammatory diseases (inflammatory bowel disease, multiple cerebrosclerosis, arthritis, etc.), neurodegenerative diseases (extrapyramidal disorder, Alzheimer's disease, muscular dystrophy, lumbar spinal canal stenosis, etc.), diabetes, shock, head trauma, renal failure, hyperalgesia, etc. Moreover, these compounds are useful as agents against retroviruses (HIV etc.), sensitizers in treating cancer and immunosuppressants.

  式 (I) 所代表的融合哒嗪衍生物或其药学上可接受的盐（其中各符号的含义如说明书中所定义）。 由于能抑制多（ADP-核糖）聚合酶，式（I）代表的化合物可作为各种缺血性疾病（脑、脊髓、心脏、消化道、骨骼肌、视网膜等）、炎症性疾病（炎症性肠病）的预防和/或治疗药物。炎症性疾病（炎症性肠病、多发性脑硬化症、关节炎等）、神经退行性疾病（锥体外系障碍、阿尔茨海默病、肌肉萎缩症、腰椎管狭窄症等）、糖尿病、休克、头部创伤、肾功能衰竭、痛觉减退等。此外，这些化合物还可用作抗逆转录病毒（HIV 等）的药物、治疗癌症的增敏剂和免疫抑制剂。
• AMIDE COMPOUND AND USE OF SAME FOR NOXIOUS ARTHROPOD CONTROL
  申请人：Sumitomo Chemical Company Limited

  公开号：EP3178322A1

  公开（公告）日：2017-06-14

  There is rovided a noxious arthropod controlling agent containing an amide compound of formula (I): wherein R1 represents a C1-C8 chain hydrocarbon group optionally having one or more groups selected from Group A, R2 represents a hydrogen atom or the like, R3 represents a hydrogen atom or the like, R5 and R6 are the same or different, and independently represent a hydrogen atom or the like, Y represents an oxygen atom or the like, m represents 0, 1, 2, 3, 4, 5, 6 or 7, and Q represents a C1-C8 chain hydrocarbon group optionally having one or more atoms or groups selected from Group D.

  提供了一种含有式（I）酰胺化合物的有害节肢动物控制剂： 其中 R1 代表 C1-C8 链烃基，可选择具有选自 A 组的一个或多个基团；R2 代表氢原子或类似物；R3 代表氢原子或类似物；R5 和 R6 相同或不同，且独立地代表氢原子或类似物；Y 代表氧原子或类似物；m 代表 0、1、2、3、4、5、6 或 7；以及 Q 代表 C1-C8 链烃基，可选择具有选自 D 组的一个或多个原子或基团。
• Pd/NBE-Catalyzed One-Pot Modular Synthesis of Polycyclic Fused δ-Lactams and Investigation of Room-Temperature Phosphorescence
  作者：Chen Chen、Chang Ni、Jia-Hui Song、Lu-Yao Ding、Xiao-Xu Zhang、Hongda Guo、Kui Wang、Zhijun Chen、Bolin Zhu

  DOI：10.1021/acscatal.4c03757

  日期：2024.8.16

  one-pot approach for the synthesis of polycyclic fused δ-lactams via the sequential phosgenation, Pd/NBE-catalyzed ortho-carbamoylation/ipso-Heck-type cyclization, and C–H activation from readily available aryl halides, amines, and triphosgenes. This reaction stands out as the first example of the in situ carbamoyl chloride formation from readily available amine precursors, presenting an alternative to

  先进的合成方法的进步可以简化反应过程，同时提高分子的复杂性，这是化学领域永恒的必要条件。催化一锅级联方法在有效构建具有卓越化学选择性的复杂分子中发挥着至关重要的作用。在此，我们提出了一种通过顺序光气化、Pd/NBE催化的邻位氨基甲酰化/原位-Heck型环化以及从容易获得的芳基卤化物中进行C-H活化来合成多环稠合δ-内酰胺的一锅法，胺和三光气。该反应是由容易获得的胺前体原位形成氨基甲酰氯的第一个例子，为涉及氨基甲酰氯的现有转化提供了替代方案。这些方法的实际意义通过以快速且经济有利的方式有效合成 81 种多环稠合 δ-内酰胺而无需中间纯化而得到体现。此外，这些转变具有可扩展性，并且与各种天然产物和药物兼容，进一步强调了该策略的有效性。我们合成的多环稠合δ-内酰胺表现出相对刚性和共面的结构，表现出独特的室温磷光特性，已被用于防伪和高安全级数据加密。
• Pyridinium Salt Forming Rh(III)-Catalyzed Annulation Reaction of Secondary Allylamines with Internal Alkynes and Its Application to Surface Modification of a Mesoporous Material
  作者：Ye Ri Han、Su-Hyang Shim、Dong-Su Kim、Chul-Ho Jun

  DOI：10.1021/acs.orglett.7b03654

  日期：2018.1.5

  A Rh(III)-catalyzed C H activation reaction has been developed for the preparation of pyridinium salts from secondary allylamines and internal alkynes. The pyridinium salts formed by this N-annulation reaction have interesting fluorescence properties. This protocol has been applied to the surface modification of mesoporous silica materials to generate functionalized silica that can be used for the detection of nitrobenzene.